DaVita Inc.
Kidney Care and Dialysis ServicesFounded 1999- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
DaVita Inc.
Company History
Founded 1999 in Denver, Colorado
Last reviewed: 2025-07-15 · By Swet Parvadiya
$12.82 billion in annual revenue from treating patients whose kidneys have failed, with a business model where commercial insurance patients generate three to four times the revenue of Medicare patients and a single payer mix shift can move earnings by hundreds of millions of dollars. That is DaVita in 2024, a company at an inflection point where federal policy is pushing home dialysis and transplants, commercial insurers are managing costs aggressively, and the dialysis duopoly with Fresenius faces persistent antitrust scrutiny. The company operates 2,657 US centers treating 200,800 patients, with an additional 509 international centers treating 80,300 patients. Revenue per treatment was $391.32, patient care costs were $258.12, and operating income was $2.09 billion. CEO Javier Rodriguez has guided to adjusted operating income of $2.01–$2.16 billion in 2025, with free cash flow of $1.00–$1.25 billion funding continued share repurchases. Berkshire Hathaway's 45% stake provides both validation and volatility. The strategic challenge is navigating the transition from volume-based dialysis provider to value-based kidney care company while maintaining the profitability that supports aggressive capital returns.
Kent J. Thiry is an American healthcare executive who served as Chairman and CEO of DaVita Inc. from 1999 to 2019. A graduate of Harvard Business School and Stanford Law School, Thiry was recruited to lead DaVita when it was a struggling regional dialysis provider. He transformed the company through the Gambro acquisition, cultural innovation, and operational excellence, building DaVita into one of the largest kidney care companies in the world. Thiry also pursued political ambitions, running for Colorado governor and US Senate. He is known for his distinctive corporate culture philosophy and public speaking on healthcare and leadership.
Total Renal Care merged with Renal Treatment Centers to form a new company that would be renamed DaVita—Italian for 'giving life.' The merger created a national dialysis provider with approximately 300 centers, but the company struggled operationally and financially in its early years.
Kent Thiry was recruited as CEO of DaVita, bringing experience from Vivra Specialty Partners and consulting. Thiry implemented a transformative strategy including cultural renewal, operational discipline, and the 'village' concept that treated each dialysis center as a community. His leadership would define DaVita for the next two decades.
DaVita acquired Gambro Healthcare's US dialysis business for approximately $3.5 billion, more than doubling the company's size. Gambro was the third-largest dialysis provider in the United States, and the acquisition created a national network of approximately 1,500 centers, establishing DaVita as a true competitor to Fresenius Medical Care.
DaVita acquired HealthCare Partners, a large physician group management company, for approximately $4.42 billion. HealthCare Partners operated medical groups in California, Colorado, Florida, Nevada, New Mexico, and Washington, providing primary and specialty care to approximately 1.7 million patients. The acquisition was intended to create an integrated care platform.
DaVita announced the sale of DaVita Medical Group (formerly HealthCare Partners) to Optum for approximately $4.9 billion in cash. The sale reflected the challenges of integrating physician group management with dialysis operations and returned DaVita to its core kidney care focus. The transaction was completed in 2019.
Javier Rodriguez succeeded Kent Thiry as CEO of DaVita, after serving as COO. Rodriguez's appointment signaled a focus on operational execution, integrated kidney care, and value-based care initiatives. Thiry remained as Executive Chairman until fully stepping down in 2020.
Warren Buffett's Berkshire Hathaway began accumulating DaVita shares, eventually reaching approximately 45% ownership by 2025. The investment reflected Buffett's confidence in DaVita's predictable cash flows, market position, and capital returns. The concentrated ownership has provided both stability and volatility.
DaVita expanded its Integrated Kidney Care (IKC) platform, managing patients in risk-based arrangements with Medicare Advantage plans and CMS innovation models. The IKC platform grew to manage tens of thousands of patients, positioning DaVita as a care coordinator beyond traditional dialysis services.
DaVita accelerated investments in home dialysis capabilities, including peritoneal dialysis and home hemodialysis, in response to federal policy incentives. The Center Without Walls platform supported remote patient monitoring and care coordination for home dialysis patients.
DaVita reported FY2024 revenue of $12.82 billion, a 5.6% increase from 2023, with operating income of $2.09 billion. The company repurchased 9.83 million shares for $1.38 billion, reducing the share count by 9.3%. International operations expanded through acquisitions in Chile, Ecuador, and Colombia.
DaVita acquired Gambro Healthcare's US dialysis business to more than double its size and create a national network competitive with Fresenius Medical Care. Gambro was the third-largest dialysis provider in the United States, and the acquisition established the US dialysis duopoly.
DaVita acquired HealthCare Partners to diversify beyond dialysis into physician group management and integrated care. HealthCare Partners operated medical groups in California, Colorado, Florida, Nevada, New Mexico, and Washington, serving approximately 1.7 million patients.
DaVita has acquired dialysis providers in multiple international markets including Brazil, Colombia, Chile, Ecuador, Malaysia, and Saudi Arabia to expand its global footprint. These acquisitions target markets with underdeveloped dialysis infrastructure and growing demand.